

**ADVANCEMENT OF RESEARCH FOR
MYOPATHIES (ARM)**

**FINANCIAL STATEMENTS
AND
AUDITORS' REPORT**

SEPTEMBER 30, 2009

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
SEPTEMBER 30, 2009**

TABLE OF CONTENTS

	<u>PAGE</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS	
Statement of Financial Position	2
Statement of Activities	3
Statement of Functional Expenses	4
Statement of Cash Flows	6
Notes to Financial Statements	7

ALBERT DAVIDOO & COMPANY
Certified Public Accountants



INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Advancement of Research for Myopathies (ARM)
Reseda, California

We have audited the accompanying statements of financial position of Advancement of Research for Myopathies – ARM (the “Organization”) (a California non-profit Organization) as of September 30, 2009, and the related statements of activities, functional expenses, and cash flows for the year then ended. These financial statements are the responsibility of the Organization’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Advancement of Research for Myopathies (ARM) as of September 30, 2009, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

May 12, 2010

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Statement of Financial Position

September 30, 2009

ASSETS

Current Assets	
Cash	\$ 55,993
Interest receivable	<u>822</u>
Total current assets	56,815
Fixed assets	
Office equipment	401
Less accumulated depreciation	<u>401</u>
Total fixed assets	<u>-</u>
Total assets	<u>\$ 56,815</u>

LIABILITIES AND NET ASSETS

Current liabilities	
Accrued expenses	\$ <u>4,315</u>
Total current liabilities	4,315
Contingencies	-
Net assets - Unrestricted	<u>52,500</u>
Total liabilities and net assets	<u>\$ 56,815</u>

The accompanying notes are an integral part of these financial statements.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Statement of Activities
Year Ended September 30, 2009

REVENUES:

Contributions and grants	\$ 502,098
Interest income	<u>9,454</u>
Total revenues	511,552

EXPENSES:

Program services:	
Primary research	105,217
Research development and patient services	<u>360,862</u>
Total program services	466,079
Support services:	
General and administrative	31,291
Fundraising	<u>226,151</u>
Total support services	<u>257,442</u>
Total expenses	<u>723,521</u>
Decrease in unrestricted net assets	(211,969)
Unrestricted net assets at beginning of year	<u>264,469</u>
Unrestricted net assets at end of year	<u>\$ 52,500</u>

The accompanying notes are an integral part of these financial statements.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Functional Expenses
For the Year ended September 30, 2009

	<u>PROGRAM SERVICES</u>		<u>SUPPORT SERVICES</u>			
	<u>Program Services</u>	<u>Total Program Services</u>	<u>General and Administrative</u>	<u>Fund raising</u>	<u>Total Support Services</u>	<u>Total Expenses</u>
Grants and allocations	\$ 435,558	\$ 435,558	\$ -	\$ -	\$ -	\$ 435,558
Fund-raising activities	-	-	-	128,305	128,305	128,305
Other salaries and wages	27,949	27,949	16,368	44,317	60,685	88,634
Printing and visual aids	-	-	-	22,971	22,971	22,971
Rent	-	-	1,384	12,454	13,838	13,838
Legal and professional fees	-	-	8,450	-	8,450	8,450
Payroll taxes	2,572	2,572	1,469	4,042	5,511	8,083
Credit card fees	-	-	-	4,242	4,242	4,242
Office expenses	-	-	384	3,458	3,842	3,842
Postage and shipping	-	-	299	2,687	2,986	2,986
Telephone	-	-	1,459	1,459	2,918	2,918
Supplies	-	-	574	574	1,148	1,148
Bank fees	-	-	513	513	1,026	1,026
Travel	-	-	-	865	865	865
Outside services	-	-	57	228	285	285
Licenses and permits	-	-	165	-	165	165

The accompanying notes are an integral part of these financial statements.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)
Statement of Functional Expenses
For the Year ended September 30, 2009

	<u>PROGRAM SERVICES</u>		<u>SUPPORT SERVICES</u>			
	<u>Program Services</u>	<u>Total Program Services</u>	<u>General and Administrative</u>	<u>Fund raising</u>	<u>Total Support Services</u>	<u>Total Expenses</u>
Depreciation	-	-	93	-	93	93
Meals and Entertainment	-	-	36	36	72	72
Dues and subscriptions	-	-	40	-	40	40
Total	<u>\$ 466,079</u>	<u>\$ 466,079</u>	<u>\$ 31,291</u>	<u>\$ 226,151</u>	<u>\$ 257,442</u>	<u>\$ 723,521</u>

The accompanying notes are an integral part of these financial statements.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Statement of Cash Flows
Year Ended September 30, 2009

CASH FLOWS FROM OPERATING ACTIVITIES:

Decrease in unrestricted net assets	\$(211,969)
Adjustments to reconcile decrease in unrestricted net assets to net cash used in operating activities:	
Depreciation	93
Changes in assets and liabilities:	
Decrease in receivables	3,968
Increase in accrued expenses	<u>1,382</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	 (206,526)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	 <u>262,519</u>
CASH AND CASH EQUIVALENTS AT END OF YEAR	 <u>\$ 55,993</u>

The accompanying notes are an integral part of these financial statements.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2009

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Activities

Advancement of Research for Myopathies (the “Organization”) is a non-profit corporation organized to provide funds for development of effective treatments for autosomal recessive inclusion body myopathy (IBM2). IBM2 is also known as quadriceps spring myopathy (QSM), distal myopathy with rimmed vacuoles (DMRV or nonka’s myopathy), or hereditary inclusion body myopathy (HIBM).

Basis of Accounting

The financial statements of Advancement of Research for Myopathies have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles.

Statement of Cash Flows

For the purposes of the statement of cash flows, the Organization considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

Fixed Assets

Property and equipment are stated at cost. Depreciation on assets is provided for in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service lives. The straight-line method of depreciation is followed for all assets.

Income Taxes

Advancement of Research for Myopathies is exempt from federal income taxes under Section 501 (c) (3) of the Internal Revenue Code and did not conduct unrelated business activities. Therefore, Advancement of Research for Myopathies has made no provision for federal income taxes in the accompanying financial statements.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2009

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Restriction of Funds

All funds in the various bank accounts are unrestricted funds.

NOTE 2 – BASIS FOR GRANTS PAYABLE

Grants awards may extend a period of 1-3 years and are paid on a quarterly basis. The Organization records the initial year's liabilities and related expenses for the awarded grants after recommended for approval by the Organization's independent scientific peer reviewers and approved by the Board of Directors. Funding of the remaining committed future amounts of grants is contingent upon satisfactory scientific and/or medical review and the availability of funds. For the year ended September 30, 2009, \$330,341 in grants were paid to HIBM Research Group, Inc., which is a non-profit organization with the main purpose of engaging in medical research regarding Hereditary Inclusion Body Myopathies (HIBM).

NOTE 3 – FUNDRAISING ACTIVITIES

Advancement of Research for Myopathies (ARM) organizes special events to increase awareness and raise funds for biomedical research.

NOTE 4 – FIXED ASSETS

As of September 30, 2009, fixed assets consist of:

Office equipment	\$ 401
Less accumulated depreciation	<u>401</u>
	<u>\$ -</u>

ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2009

NOTE 5 - COMMITMENTS

The Organization entered into a joint lease with one other tenant for office space rental in June 2009. The lease is for one year expiring on June 30, 2010.

<u>YEAR</u>	<u>RENT EXPENSE</u>
2010	\$ 3,267
2011	-
2012	-
2013	-
2014	-
TOTAL	\$ <u>3,267</u>

Total rent expense for the year was \$13,838.

NOTE 6 – MAJOR CONTRIBUTIONS

During the year Advancement of Research for Myopathies (ARM) had contributions from seven major donors (over \$ 5,000), representing 25% of the contribution revenues and 15% of the overall revenues.

NOTE 7 - OFF-BALANCE SHEET CREDIT RISK

Advancement of Research for Myopathies (ARM) periodically maintains balances in its various cash accounts in excess of \$250,000. Such excess is not insured by the Federal Depository Insurance Corporation (FDIC).